Stay updated with Almirall’s latest news. Explore our newsroom, access multimedia resources and company information, or browse our full archive of press releases.
We are committed to maintaining transparent and proactive communication with stakeholders and the healthcare community, providing timely information on our ongoing mission to transform patients' lives through innovative skin health solutions.
Stay informed with our most recent press releases. In this section, you will find comprehensive coverage of our research advancements, strategic partnerships, and corporate milestones.
1/5
Almirall has entered a collaboration and licensing agreement with Chinese company CrystalO for the discovery and development of novel small molecules in medical dermatology.
At Almirall, sustainability is an integral part of how we create long-term value and contribute positively to society. Guided by our Act4Impact strategy, we continuously work to embed responsible business practices into the way we operate, make decisions and drive innovation across our organisation.
At Almirall, sustainability is an integral part of how we create long-term value and contribute positively to society. Guided by our Act4Impact strategy, we continuously work to embed responsible business practices into the way we operate, make decisions and drive innovation across our organisation.
Almirall has entered a collaboration and licensing agreement with Chinese company CrystalO for the discovery and development of novel small molecules in medical dermatology.
At Almirall, innovation begins with the curiosity, dedication and expertise of our teams. Every day, scientists, researchers and multidisciplinary experts work together to advance the understanding of skin diseases and address some of the most complex challenges in medical dermatology.
At Almirall, our purpose is to help patients realize their hopes and dreams for a healthy life. This commitment guides everything we do, from advancing scientific knowledge in medical dermatology to fostering meaningful collaboration with healthcare professionals and patient communities around the world.
Today, we announced a strategic research collaboration and licensing agreement with Certest Biotec, S.L., through its pharmaceutical division, Certest Pharma. Through this collaboration, we will jointly discover and clinically develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.
To support your reporting and research, we provide a selection of essential resources, including our corporate profile, high-resolution media assets, and detailed reports on our pipeline focused on medical dermatology. These materials are designed to offer a clear and in-depth perspective on Almirall’s global operations and our commitment to scientific excellence.
To receive notifications when new events are added to this calendar, please sign up for our Email Alert service.
Our yearly figures. Discover how we performed in the last year and where we are heading. Information issued by the company to the National Stock Exchange Commission (CNMV).
